A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

I4D-MC-JTJI -

The main purpose of this study is to investigate the safety of prexasertib (LY2606368) in combination with other anti-cancer drugs (cisplatin or cetuximab) and radiation therapy in participants with locally advanced head and neck cancer. The study has two parts (A and B). Participants will only enroll in one part.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Head and Neck Cancer
What the trial is testing?
Cetuximab, Cisplatin, Prexasertib
Could I receive a Placebo?
No
Enrollment Goal
70
Trial Dates
Feb 24, 2016 - Jan 14, 2019
How long will I be in the trial?
Your participation will last ~ 7-8 weeks depending on how well you tolerate therapy. There is also a follow up period of ~ 1 year.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.